Glioblastoma Multiforme (GBM) is an aggressive and rapidly progressing brain tumor originating from glial cells. Known for its high recurrence rates and resistance to standard treatments, GBM remains a significant challenge in oncology. However, the Glioblastoma Multiforme market is witnessing steady advancements in therapeutic approaches, with new